×
Tourmaline Bio EBITDA 2020-2025 | TRML
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Tourmaline Bio ebitda from 2020 to 2025. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
View More
Tourmaline Bio EBITDA 2020-2025 | TRML
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Tourmaline Bio ebitda from 2020 to 2025. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
Related Stocks
Company Name
Market
Cap
Chugai Pharmaceutical (CHGCY)
$76.6B
Zoetis (ZTS)
$69B
Takeda Pharmaceutical (TAK)
$46.7B
Daiichi Sankyo, - (DSNKY)
$41.7B
BeOne Medicines - (ONC)
$27.4B
Sandoz Group AG (SDZNY)
$24.6B
Summit Therapeutics (SMMT)
$18.6B
Merck (MKKGY)
$17.2B
Shionogi (SGIOY)
$14.2B
United Therapeutics (UTHR)
$13.3B
Neurocrine Biosciences (NBIX)
$13.2B
Orion OYJ (ORINY)
$11B
IPSEN (IPSEY)
$10.3B
Stevanato Group S.p.A (STVN)
$7.6B
Corcept Therapeutics (CORT)
$7.6B
Madrigal Pharmaceuticals (MDGL)
$7B
Grifols, S.A (GRFS)
$6.7B
Ionis Pharmaceuticals (IONS)
$6.6B
Hikma Pharmaceuticals Plc (HKMPF)
$6.2B
Ono Pharmaceutical (OPHLF)
$5.1B
Soleno Therapeutics (SLNO)
$4.1B
Crinetics Pharmaceuticals (CRNX)
$3B
Hypermarcas (HYPMY)
$3B
Catalyst Pharmaceuticals (CPRX)
$2.7B
AMNEAL PHARMACEUTICALS, INC (AMRX)
$2.6B
NewAmsterdam Pharma (NAMS)
$2.4B
Centessa Pharmaceuticals (CNTA)
$1.9B
BioCryst Pharmaceuticals (BCRX)
$1.8B
Ocular Therapeutix (OCUL)
$1.8B
ARS Pharmaceuticals (SPRY)
$1.7B